| Literature DB >> 22848709 |
Giovanni Lombardi1, Patrizia Lanteri, Rosa Graziani, Alessandra Colombini, Giuseppe Banfi, Roberto Corsetti.
Abstract
Cycling is a not weight-bearing activity and is known to induce bone resorption. Stage races are really strenuous endurance performances affecting the energy homeostasis. The recently highlighted link, in the co-regulation of bone and energy metabolism, demonstrates a central role for the equilibrium between carboxylated and undercarboxylated forms of osteocalcin. Aim of this study was to understand the acute physiological responses to a cycling stage race in terms of bone turnover and energy metabolism and the possible co-regulative mechanisms underlying their relationship. We studied nine professional cyclists engaged in 2011 Giro d'Italia stage race. Pre-analytical and analytical phases tightly followed academic and anti-doping authority's recommendations. Bone and energy metabolism markers (bone alkaline phosphatase, tartrate-resistant acid phosphatase 5b, total and undercarboxylated osteocalcin, leptin and adiponectin) and related hormones (cortisol and testosterone) were measured, by Sandwich Enzyme Immunoassays, at days -1 (pre-race), 12 and 22 during the race. The power output and the energy expenditure (mean and accumulated) were derived and correlated with the biochemical indexes. During the race, bone metabolism showed that an unbalance in behalf of resorption, which is enhanced, occurred along with a relative increase in the concentration of the undercarboxylated form of osteocalcin that was indirectly related to the enhanced energy expenditure, through adipokines modifications, with leptin decrease (high energy consumption) and adiponectin increase (optimization of energy expenditure). The exertion due to heavy effort induced a decrease of cortisol, while testosterone levels resulted unchanged. In conclusion, during a 3-weeks stage race, bone metabolism is pushed towards resorption. A possible relationship between the bone and the energy metabolisms is suggested by the relative correlations among absolute and relative concentrations trends of undercarboxylated OC, adipokines concentrations, BMI, fat mass (%), power output and the derived energy expenditure.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22848709 PMCID: PMC3407078 DOI: 10.1371/journal.pone.0042077
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of the route.
| Day | Stage | Stage Lenght (km) | Level Difference (m) | Kind of Stage | Blood drawing |
| −3 | / | / | / | / | Official Antidoping |
| −2 | / | / | / | / | |
| −1 | / | / | / | / | Study |
| 1 | 1 | 19.3 | 96 | Time Trial | |
| 2 | 2 | 244.0 | 780 | Flat | |
| 3 | 3 | 173.0 | 2340 | Flat | |
| 4 | 4 | 216.0 | 2779 | Medium Mountain | |
| 5 | 5 | 191.0 | 3637 | Medium Mountain | Official Antidoping |
| 6 | 6 | 216.0 | 3200 | Flat | |
| 7 | 7 | 110.0 | 2796 | Medium Mountain | |
| 8 | 8 | 217.0 | 912 | Flat | |
| 9 | 9 | 169.0 | 5412 | Mountain | |
| 10 | Rest | / | / | / | |
| 11 | 10 | 159.0 | 882 | Flat | |
| 12 | 11 | 144.0 | 3097 | Medium Mountain | Study |
| 13 | 12 | 184.0 | 463 | Flat | |
| 14 | 13 | 167.0 | 4664 | Mountain | |
| 15 | 14 | 210.0 | 6643 | Mountain | |
| 16 | 15 | 229.0 | 9490 | Mountain | |
| 17 | Rest | / | / | / | |
| 18 | 16 | 12.7 | 756 | Time Trial | |
| 19 | 17 | 230.0 | 5336 | Medium Mountain | |
| 20 | 18 | 151.0 | 1949 | Flat | Official Antidoping |
| 21 | 19 | 209.0 | 3569 | Mountain | |
| 22 | 20 | 242.0 | 3464 | Mountain | Study |
| 23 | 21 | 31.5 | 67 | Time Trial |
In the Table are reported the correspondence between day, length (km), level difference (m) of each stage along with the kind of stage and the blood sampling performed for this study and the blood sampling for official anti-doping testing.
Anthropometric and power-related measurements across the stage race.
| Parameters | day -1 | day 12 | day 22 | P-value |
| Height (m) | 1.82±0.05 | / | / | / |
| Weight (kg) | 69.1±5.24a | 68.9±4.94a | 67.4±5.06b | <0.05 |
| Mean power output (W) | / | 214.3±14.96a | 256.2±14.63b | <0.001 |
| Mean power output/Weight (W/kg) | / | 3.1±0.17 | 3.7±0.16 | <0.001 |
| Accumulated power output (W) | / | 1929.0±134,60a | 2305,5±131,69b | <0.001 |
| Accumulated power output/Weight (W/kg) | / | 27.9±1.56 | 33.4±1.43 | <0.001 |
| Mean net energy expenditure (kcal) | 2213.1±156.01a | 3401.5±249.41b | 3755.9±239.96c | <0.001 |
| Accumulated net energy expenditure (kcal) | 2213.1±156.01a | 30613.4±2244.66b | 33803.0±2159.62c | <0.001 |
In the Table are reported the results of the measurements at the same time-points of blood sampling, with the exception of the height that is reported only for day -1.
Mean power output and accumulated power output, as both raw data and corrected for body weight, refer to the mean or the sum, respectively, of the consecutive measurements relative to the period preceding the blood sampling. The same applies to mean net energy expenditure and accumulated net energy expenditure for whom the rest values (day -1) correspond to the basal metabolic rate. Measurements are expressed as mean±SD and values bearing different letters in apex are significantly different (p<0.05).
Figure 1Modification of serum bone markers activity over the race.
The Figure shows the trends of serum BAP (panel A) and serum TRAP5b (panel B) over the stage race. ** indicates a significant variation (p<0.01).
Figure 2Modification of plasma osteocalcin levels and relative concentration of Glu-OC over the race.
The Figure shows the trends of plasma total OC (panel A), plasma Glu-OC (panel B) and relative percentage concentration of Glu-OC (panel C) over the stage race. ** and * indicate significant variations (p<0.01 and p<0.05, respectively).
Figure 3Modification of adipokines levels over the race.
The Figure shows the trends of serum adiponectin (panel A) and serum leptin (panel B) over the stage race. ***, ** and * indicate significant variations (p<0.001, p<0.01 and p<0.05, respectively).
Figure 4Modification of cortisol and testosterone concentrations over the race.
The Figure shows the trends of serum cortisol (panel A) and serum testosterone (panel B) over the stage race. ** indicates a significant variation (p<0.01).